| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Outlook for 2025
Based on currently available information, the company is affirming guidance for full year 2025 revenues before reimbursable expenses in a range of $1.58 billion to $1.66 billion. The company is also affirming guidance for full year 2025 adjusted EBITDA as a percentage of revenues before reimbursable expenses (1) in a range of 14.0% to 14.5% and adjusted diluted earnings per share (1) in a range of $6.80 to $7.60.
Posted In: HURN